US › Healthcare

Atea Pharmaceuticals Inc (AVIR)

US · Healthcare · Biotechnology

$4.70+1.95%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-45.4M

Profit YoY

-32.6%

EPS

$-0.57

EPS estimate

$-0.56

EPS came in at -0.57 against a street estimate of -0.56 — a miss of 3.4%.

Key statistics

Market cap

$376.1M

Forward P/E

0.0

P/B

1.61

Book value

$2.92

EPS (TTM)

$-2.11

52-week high

$6.45

52-week low

$2.78

50-day MA

$4.58

200-day MA

$4.35

Beta

0.32

Analyst view

Analysts rate Atea Pharmaceuticals Inc a hold (1 buy, 1 hold, 1 sell out of 3) with an average price target of $8.67.

Shareholding

Insiders

13.40%

Institutions

79.71%

Largest institutional holders

Fund	Stake
FMR Inc	14.93%
BlackRock Inc	10.54%
BML Capital Management LLC	8.82%
TANG CAPITAL MANAGEMENT LLC	6.02%
Vanguard Capital Management, LLC	4.06%
Bain Capital Life Sciences Investors, LLC	2.95%
Two Sigma Investments LLC	2.33%
Geode Capital Management, LLC	2.18%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Atea Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.